Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?

Joint Bone Spine. 2022 Nov;89(6):105454. doi: 10.1016/j.jbspin.2022.105454. Epub 2022 Aug 12.
No abstract available

Keywords: JAK inhibitors; Rheumatoid arthritis.

Publication types

  • Editorial

MeSH terms

  • Antirheumatic Agents* / pharmacology
  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Janus Kinase Inhibitors* / therapeutic use
  • Odds Ratio

Substances

  • Janus Kinase Inhibitors
  • Antirheumatic Agents